Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • TA218
  • Published: 
Download guidance (PDF)

Update information

February 2014: Implementation section updated to clarify that azacitidine is recommended as an option for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

ISBN: 978-1-4731-3448-5